VYVANSE Demonstrates Significant Efficacy For Treatment Of ADHD For Up To 12 Hours After Administration

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced that Biological Psychiatry published the results of a study showing VYVANSE™ (lisdexamfetamine dimesylate), the first prodrug stimulant for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), provided significant efficacy in children for up to 12 hours. ...

Write comment to this article:

Subject:

Name:

email or site:

Code: